Poniard Announces Positive Incremental Efficacy And Safety Data From Ongoing Phase 2 Picoplatin Trial In Hormone-Refractory Prostate Cancer

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced positive incremental data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic hormone-refractory prostate cancer (HRPC).

More: continued here

Filed under: Prostate on October 27th, 2008